<?xml version="1.0" encoding="UTF-8"?>
<p>In accordance with previous studies, SVR rates after treatment with G/P were excellent and no serious adverse events related to therapy occurred[
 <xref rid="pone.0229239.ref020" ref-type="bibr">20</xref>,
 <xref rid="pone.0229239.ref022" ref-type="bibr">22</xref>â€“
 <xref rid="pone.0229239.ref025" ref-type="bibr">25</xref>,
 <xref rid="pone.0229239.ref038" ref-type="bibr">38</xref>]. During follow-up, only one HCV reinfection was detected which might be due to the integrated management of PWIDs at our low-threshold facilities in Vienna that offer counseling and syringe exchange services along with medical treatment for PWIDs[
 <xref rid="pone.0229239.ref039" ref-type="bibr">39</xref>].
</p>
